| Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for … M Crump, J Kuruvilla, S Couban, DA MacDonald, V Kukreti, CT Kouroukis, ... Journal of Clinical Oncology 32 (31), 3490-3496, 2014 | 442 | 2014 |
| Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group CM Canil, MJ Moore, E Winquist, T Baetz, M Pollak, KN Chi, S Berry, ... Journal of Clinical Oncology 23 (3), 455-460, 2005 | 242 | 2005 |
| Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma: a phase II study by the National Cancer … M Crump, T Baetz, S Couban, A Belch, D Marcellus, K Howson‐Jan, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 205 | 2004 |
| Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer … T Baetz, A Belch, S Couban, K Imrie, J Yau, R Myers, K Ding, N Paul, ... Annals of Oncology 14 (12), 1762-1767, 2003 | 188 | 2003 |
| Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study LH Sehn, A Goy, FC Offner, G Martinelli, MD Caballero, O Gadeberg, ... Journal of Clinical Oncology 33 (30), 3467, 2015 | 179 | 2015 |
| Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma S Verma, I Quirt, D McCready, K Bak, M Charette, N Iscoe, ... Cancer 106 (7), 1431-1442, 2006 | 175 | 2006 |
| Phase II study of perifosine in previously untreated patients with metastatic melanoma DS Ernst, E Eisenhauer, N Wainman, M Davis, R Lohmann, T Baetz, ... Investigational new drugs 23, 569-575, 2005 | 136 | 2005 |
| Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC) SL Moulder, VF Borges, T Baetz, T Mcspadden, G Fernetich, RK Murthy, ... Clinical Cancer Research 23 (14), 3529-3536, 2017 | 129 | 2017 |
| Predictors of immunotherapy-induced immune-related adverse events A Kartolo, J Sattar, V Sahai, T Baetz, JM Lakoff Current Oncology 25 (5), 403-410, 2018 | 102 | 2018 |
| The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population J Sattar, A Kartolo, WM Hopman, JM Lakoff, T Baetz Journal of geriatric oncology 10 (3), 411-414, 2019 | 65 | 2019 |
| Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome A Alhejaily, AG Day, HE Feilotter, T Baetz, DP LeBrun Clinical Cancer Research 20 (6), 1676-1686, 2014 | 65 | 2014 |
| Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome A Johri, T Baetz, PA Isotalo, RL Nolan, AJ Sanfilippo, G Ropchan Canadian Journal of Cardiology 25 (6), e210-e212, 2009 | 65 | 2009 |
| Discordance between conclusions stated in the abstract and conclusions in the article: analysis of published randomized controlled trials of systemic therapy in lung cancer AK Altwairgi, CM Booth, WM Hopman, TD Baetz Journal of clinical oncology 30 (28), 3552-3557, 2012 | 56 | 2012 |
| Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12 J Kuruvilla, DA MacDonald, CT Kouroukis, M Cheung, HJ Olney, ... Blood, The Journal of the American Society of Hematology 126 (6), 733-738, 2015 | 52 | 2015 |
| MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma RS Goswami, EG Atenafu, Y Xuan, L Waldron, PP Reis, T Sun, A Datti, ... Journal of clinical oncology 31 (23), 2903-2911, 2013 | 46 | 2013 |
| A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours T Baetz, E Eisenhauer, L Siu, M MacLean, K Doppler, W Walsh, B Fisher, ... Investigational New Drugs 25, 217-225, 2007 | 41 | 2007 |
| [18F]‐FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study U Metser, J Dudebout, T Baetz, DC Hodgson, DL Langer, P MacCrostie, ... Cancer 123 (15), 2860-2866, 2017 | 33 | 2017 |
| Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy A Kartolo, R Holstead, S Khalid, J Emack, W Hopman, A Robinson, ... Immunotherapy 12 (11), 785-798, 2020 | 30 | 2020 |
| Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease B Wood, S Sikdar, SJ Choi, S Virk, A Alhejaily, T Baetz, DP LeBrun Leukemia & lymphoma 54 (6), 1212-1220, 2013 | 28 | 2013 |
| Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY. 12 MC Cheung, AE Hay, M Crump, KR Imrie, Y Song, S Hassan, ... Journal of the National Cancer Institute 107 (7), djv106, 2015 | 20 | 2015 |
Lois ShepherdProfessorVerified email at ctg.queensu.ca
